Skip To Content

Revance Securities Settlement

This official website is maintained by the Claims Administrator under the supervision of Lead Counsel for the members of the Settlement Class in In re Revance Therapeutics, Inc. Securities Litigation, Case No. 3:25-cv-0018-EJR (M.D. Tenn.), which is pending in the United States District Court for the Middle District of Tennessee.

Revance Securities Settlement

If you purchased or acquired Revance Therapeutics, Inc. (“Revance”) securities during the period of February 29, 2024 through the close of the subject Merger on February 6, 2025, inclusive, including common stock (CUSIP: 761330109; ticker “RVNC”) and 1.75% fixed coupon Convertible Senior Unsecured Notes (CUSIP 761330AB5), you may be entitled to a payment from a class action settlement.

CLICK HERE TO FILE A CLAIM

The information contained on this web page is only a summary of information presented in more detail in the Notice of: (I) Pendency of Class Action; (II) Motion for Certification of Class and Approval of Proposed Settlement and Plan of Allocation; (III) Settlement Fairness Hearing; and (IV) Motion for Award of Attorneys’ Fees and Litigation Expenses (the “Notice”), which you can access by clicking here.  Since this website is just a summary, you should review the Notice for additional information.

If you are a Settlement Class Member, your legal rights will be affected by this Settlement whether you act or do not act.

Please read the Notice carefully.

SETTLEMENT CLASS: ALL PERSONS AND ENTITIES THAT PURCHASED OR ACQUIRED REVANCE SECURITIES DURING THE PERIOD OF FEBRUARY 29, 2024 THROUGH THE CLOSE OF THE SUBJECT MERGER ON FEBRUARY 6, 2025, INCLUSIVE, INCLUDING COMMON STOCK (CUSIP: 761330109; TICKER “RVNC”) AND 1.75% FIXED COUPON CONVERTIBLE SENIOR UNSECURED NOTES (CUSIP 761330AB5).

YOUR LEGAL RIGHTS AND OPTIONS IN THE SETTLEMENT
Description Due Date

DO NOTHING

Get no payment.  Remain a Class Member.  Give up your rights.

SUBMIT A PROOF OF CLAIM AND RELEASE FORM POSTMARKED OR SUBMITTED ONLINE NO LATER THAN AUGUST 28, 2026.

This is the only way to be potentially eligible to receive a payment.  If you wish to obtain a payment as a member of the Class, you will need to file a Proof of Claim and Release Form (the “Claim Form” or “Proof of Claim Form”), postmarked or submitted online no later than August 28, 2026.  See paragraph 59 of the Notice for more information regarding how to participate in the Settlement.

EXCLUDE YOURSELF FROM THE CLASS BY SUBMITTING A REQUEST FOR EXCLUSION THAT IS RECEIVED BY JULY 13, 2026.

Get no payment.  This is the only option that potentially allows you to ever be part of any other lawsuit against Defendants or any other Released Defendants Parties about the legal claims being resolved by this Settlement.  You cannot object to the proposed Settlement and cannot submit a Claim Form if you exclude yourself.  See paragraphs 60-62 of the Notice for instructions on how to request exclusion.

OBJECT TO THE SETTLEMENT SO THAT YOUR OBJECTION IS RECEIVED NO LATER THAN JULY 13, 2026.

If you do not like the proposed Settlement, the proposed Plan of Allocation, or the request for attorneys’ fees and litigation expenses, you may write to the Court and explain why you do not like them.  You cannot object to the Settlement, the Plan of Allocation or the fee and expense request unless you are a Settlement Class Member and do not exclude yourself from the Settlement Class. You do not need to submit a Claim Form to object.  If you submit a written objection, you may (but do not have to) attend the hearing. See paragraphs 63-72 of the Notice for instructions on how to object.

GO TO THE HEARING ON AUGUST 10, 2026, AT 9:00 A.M. CENTRAL TIME, AND FILE A NOTICE OF INTENTION TO APPEAR SO THAT IT IS RECEIVED NO LATER THAN 
JULY 13, 2026.

Ask to speak in Court about the fairness of the Settlement, the proposed Plan of Allocation, or the request for attorneys’ fees and litigation expenses.

What Is This Case About?

This is a securities class action against Defendants Revance Therapeutics, Inc., Mark J Foley and Tobin C. Schilke for alleged violations of the federal securities laws.  Lead Plaintiffs allege that Defendants made material misrepresentations and omissions, with scienter, in connection with the Company’s statements regarding its relationship with Teoxane SA and the tender offer and merger transaction with Crown Laboratories, Inc. (“Crown”).  Defendants deny the allegations of wrongdoing asserted in the Action and deny any liability whatsoever to any members of the Class.

How Do I Know If I Am Affected By The Settlement?

For the purposes of settlement, everyone who fits the following description is a Settlement Class Member.  Please read Paragraph 19 of the Notice for exceptions to inclusion in the Class.

All Persons and entities that purchased or otherwise acquired Revance securities during the period of February 29, 2024 through the close of the subject Merger on February 6, 2025, inclusive, including common stock (CUSIP: 761330109; ticker “RVNC”) and 1.75% fixed coupon Convertible Senior Unsecured Notes (CUSIP 761330AB5).

How Much Will My Payment Be?

Defendants have agreed to cause to be paid $17,000,000.00 in cash into escrow for the benefit of the Class.  At this time, it is not possible to make any determination as to how much individual Settlement Class Members may receive from the Settlement.  Lead Plaintiffs have proposed a plan for allocating the Net Settlement Fund to those Settlement Class Members that timely submit valid Proofs of Claim.  The Plan of Allocation proposed by Lead Plaintiffs may be found in the Notice.

The Settlement Hearing

The Settlement Hearing will be held on August 10, 2026, at 9:00 a.m., before the Honorable Eli J. Richardson, at the United States District Court, Middle District of Tennessee, Fred D. Thompson U.S. Courthouse and Federal Building, Courtroom 5C, 719 Church Street, Nashville, TN 37203.  The Court reserves the right to approve the Settlement or the Plan of Allocation, Lead Counsel’s motion for an award of attorneys’ fees and expenses, and/or any other matter related to the Settlement at or after the Settlement Hearing without further notice to the members of the Class.

Further Information

For more details regarding this case, please reference the documents filed in the case under the “Court Documents” section at the top of this website.  You may also contact the Claims Administrator or Lead Counsel for further information regarding this case.  Contact information for the Claims Administrator and Lead Counsel can be found under the “Contact Us” section of this website.